# Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine

> **NCT05861427** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 523 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Atogepant
- **DRUG:** Placebo for Atogepant

## Key facts

- **NCT ID:** NCT05861427
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-12
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 523 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861427, "Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05861427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*